Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses
Gwo‐Yu Chuang, Yen‐Ting Lai, Jeffrey C. Boyington, Cheng Cheng, Hui Geng, Sandeep Narpala, Reda Rawi, Stephen D. Schmidt, Yaroslav Tsybovsky, Raffaello Verardi, Kai Xu, Yongping Yang, Baoshan Zhang, Michael Chambers, Anita Changela, Angela R. Corrigan, Rui Kong, Adam S. Olia, Li Ou, Edward K. Sarfo, Shuishu Wang, Winston Wu, Nicole A. Doria‐Rose, Adrian B. McDermott, John R. Mascola, Peter D. Kwong
Abstract
A major hurdle to the development of an effective HIV-1 vaccine is the elicitation of serum responses capable of neutralizing circulating strains of HIV, which are extraordinarily diverse in sequence and often highly neutralization resistant. Recently, we showed how sera with 20 to 30% neutralization breadth could, nevertheless, be elicited in standard vaccine test animals by priming with the most prevalent N-terminal 8 residues of the HIV-1 fusion peptide (FP8), followed by boosting with a stabilized BG505-envelope (Env) trimer. Here, we show that subsequent boosting with a 3mut-apex-stabilized consensus C-Env trimer, modified to have the second most prevalent FP8 sequence, elicits higher neutralization breadth than that induced by continued boosting with the stabilized BG505-Env trimer. With increased neutralizing breadth elicited by boosting with a heterologous trimer containing the second most prevalent FP8 sequence, the fusion peptide-directed immune-focusing approach moves a step closer toward realizing an effective HIV-1 vaccine regimen.